Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study
We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP-contaminated sitagliptin, although continued investigation is needed.
Authors
- T. Furuno
- Yuichi Ichinose (ORCID: https://orcid.org/0000-0002-2474-785X)
- Ryoko Rikitake (ORCID: https://orcid.org/0000-0002-0232-8283)
- Takehiro Sugiyama (ORCID: https://orcid.org/0000-0001-5391-682X)
- Kenjiro Imai
- Tamaki Kakuwa (ORCID: https://orcid.org/0000-0002-6238-2003)
- Takahiro Higashi (ORCID: https://orcid.org/0000-0002-9933-2106)
- Noriko Ihana‐Sugiyama (ORCID: https://orcid.org/0000-0002-3969-7728)
- Mitsuru Ohsugi (ORCID: https://orcid.org/0000-0002-3222-8507)
- Masao Iwagami (ORCID: https://orcid.org/0000-0001-7079-0640)
- Hiroyasu Iso
- Kohjiro Ueki
Institutions
- University of Tsukuba (JP)
- National Cancer Centre Japan (JP)
- National Center for Global Health and Medicine (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1111/jdi.14281
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Sanofi
- Abbott Japan
- Kowa Company
- Boehringer Ingelheim Japan
- Japan Health Research Promotion Bureau
- Daiichi-Sankyo
- Novo Nordisk
- Astellas Pharma
- Astellas Foundation for Research on Metabolic Disorders
- Mitsubishi Tanabe Pharma Corporation
- Novartis Pharma
- Eli Lilly Japan
- Novo Nordisk Pharma
- Daiichi Sankyo Company
- Daiichi Sankyo Europe